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ABSTRACT
Introduction People presenting with shoulder pain 
considered to be of musculoskeletal origin is common 
in primary care but diagnosing the cause of the pain is 
contentious, leading to uncertainty in management. To 
inform optimal primary care for patients with shoulder 
pain, the study aims to (1) to investigate the short- term 
and long- term outcomes (overall prognosis) of shoulder 
pain, (2) estimate costs of care, (3) develop a prognostic 
model for predicting individuals’ level and risk of pain 
and disability at 6 months and (4) investigate experiences 
and opinions of patients and healthcare professionals 
regarding diagnosis, prognosis and management of 
shoulder pain.
Methods and analysis The Prognostic And Diagnostic 
Assessment of the Shoulder (PANDA- S) study is a 
longitudinal clinical cohort with linked qualitative study. 
At least 400 people presenting to general practice 
and physiotherapy services in the UK will be recruited. 
Participants will complete questionnaires at baseline, 3, 6, 
12, 24 and 36 months. Short- term data will be collected 
weekly between baseline and 12 weeks via Short 
Message Serevice (SMS) text or software application. 
Participants will be offered clinical (physiotherapist) 
and ultrasound (sonographer) assessments at baseline. 
Qualitative interviews with ≈15 dyads of patients and 
their healthcare professional (general practitioner or 
physiotherapist).
Short- term and long- term trajectories of Shoulder Pain 
and Disability Index (using SPADI) will be described, 
using latent class growth analysis. Health economic 
analysis will estimate direct costs of care and indirect 
costs related to work absence and productivity losses. 
Multivariable regression analysis will be used to develop 
a prognostic model predicting future levels of pain and 
disability at 6 months using penalisation methods to adjust 
for overfitting. The added predictive value of prespecified 
physical examination tests and ultrasound findings will 
be examined. For the qualitative interviews an inductive, 
exploratory framework will be adopted using thematic 
analysis to investigate decision making, perspectives of 
patients and clinicians on the importance of diagnostic and 
prognostic information when negotiating treatment and 
referral options.
Ethics and dissemination The PANDA- S study has 
ethical approval from Yorkshire and The Humber- Sheffield 
Research Ethics Committee, UK (18/YH/0346, IRAS 
Number: 242750). Results will be disseminated through 
peer- reviewed publications, social and mainstream 
media, professional conferences, and the patient and 
public involvement and engagement group supporting this 
study, and through newsletters, leaflets and posters in 
participating sites.
Trial registration number ISRCTN46948079.
BACKGROUND AND RATIONALE
Shoulder pain considered to be of muscu-
loskeletal origin is common, with the 
1- month population prevalence estimated 
to be between 7% and 26%,1 and an annual 
Strengths and limitations of this study
 ► Follow- up uniquely includes weekly data collection 
of the impact of shoulder pain on everyday activi-
ty, mood and work during the first 3 months after 
presentation as well as long- term pain and function 
outcomes.
 ► The use of ‘dyad’ interviews allows for a rich under-
standing of the views and experiences of clinicians 
and patients towards shoulder pain management.
 ► The COVID-19 pandemic has impacted on recruit-
ment and data collection resulting in a smaller pro-
portion of participants than planned able to attend 
face- to- face research clinics.
 ► This means the study can only investigate the added 
predictive value of a limited number of physical ex-
amination tests and ultrasound scan findings, based 
on a priori defined hypotheses.
 ► This study will include an exploration of influence of 
related (lockdown) measures and restrictions on the 
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incidence in primary care of 29.3 per 1000 person- years.2 
Annually, approximately 3% of adults in the UK will 
consult their general practitioner (GP) for shoulder pain.3 
The prognosis of shoulder pain is variable with 40%–50% 
of patients reporting persistent pain 6–12 months after 
first consulting their GP or physiotherapist,4 5 generating 
high costs to both healthcare and society.6–8 Systematic 
reviews and trials have highlighted modest short- term 
effects of commonly used treatments such as corticoste-
roid injection, therapeutic exercise and manual therapy, 
but limited evidence for long- term benefits.9–13
Diagnostic uncertainty
Achieving a definitive diagnosis for the underlying cause 
of the shoulder pain remains contentious, resulting in 
uncertainty regarding optimal management. System-
atic reviews of shoulder physical examination tests have 
highlighted variety in performance and interpretation of 
these tests, resulting in low diagnostic accuracy. There is a 
lack of evidence pertaining to combinations of signs and 
symptoms that most accurately predict patient outcome 
and response to treatment.14–17 Qualitative research has 
illustrated that GPs experience uncertainty in the diag-
nostic workup of shoulder pain and apply different strate-
gies to deal with uncertainties.18 There is limited evidence 
regarding the usefulness of diagnostic imaging, partly 
due to observations of structural changes that frequently 
do not correlate with symptom severity.19 20 The use of 
diagnostic ultrasound scans (US) has rapidly increased 
in the assessment of shoulder pain in primary care, as 
it does not involve radiation and is less expensive than 
MRI. However, evidence for their role in the diagnostic 
pathway, and in particular, their added value for esti-
mating prognosis and utility for clinical decision making, 
is still unclear.
Prognostic uncertainty
Despite evidence for the prognostic value for a range of 
factors, it is not clear which combination of prognostic 
factors optimally discriminates between patients at 
high risk versus low risk of poor outcome, with limited 
evidence for predictive performance of existing prog-
nostic models21–24 and for their usefulness in routine 
clinical practice.25 Short- term symptom change has rarely 
been investigated but may be highly predictive of long- 
term outcome, and incorporating monitoring of this early 
response in the prognostic assessment of individuals with 
shoulder pain can potentially provide better guidance 
regarding decisions for further treatment.26 27 Further-
more, little is known about the pathways that explain 
favourable or poor outcome in patients with shoulder 
pain, and generating evidence regarding the role of prog-
nostic factors along these pathways may allow the identifi-
cation of new targets for treatment.
In summary, given the high impact of shoulder pain, 
diagnostic uncertainty, variable prognosis and limited 
evidence for long- term treatment outcomes, there is 
a clear need for research investigating short- term and 
long- term outcomes of shoulder pain with the aim of 
improving the primary care management of shoulder 
pain in future.
Aims and objectives
The overall aim of this study is to enhance the primary 
care management of patients with shoulder pain, by inves-
tigating the short and long- term outcomes of shoulder 
pain and developing a prediction model using diagnostic 
and prognostic information that will provide reliable 
individualised risk prediction for 6- month outcomes of 
shoulder pain and disability. Specific objectives are to:
1. Describe the short term (≤6 months) and long term 
(up to 3 years) overall prognosis in people presenting 
with shoulder pain, in terms of pain and function tra-
jectories and impact on sleep, mood, work and health- 
related quality of life.
2. Describe healthcare resource use and estimate the 
costs associated with care for shoulder pain; and de-
scribe and estimate time off work and loss of produc-
tivity associated with shoulder pain in the short term (6 
months) and long term (up to 3 years).
3. Develop a prognostic model for predicting individuals’ 
level and risk of pain and disability at 6 months after 
presentation, based on self- reported candidate prog-
nostic factors, and estimate and internally validate the 
model’s predictive performance and clinical utility.
4. Estimate the added prognostic value of physical exam-
ination tests and US findings in the prediction of fu-
ture pain and disability.
5. Explore candidate predictors of response to common-
ly used treatments in a real- life, observational setting.
6. Explore perspectives, influences and uncertainty of 
patients and clinicians regarding the importance of di-
agnostic and prognostic information when negotiating 
treatment and referral options, and making decisions 
about the management of shoulder pain.
METHODS
Study design
Multicentre observational cohort study, including 
patients presenting with shoulder pain in general prac-
tices, and National Health Service (NHS) physiotherapy 
services (including self- referrers to physiotherapy), with a 
linked qualitative study. Figure 1 details the recruitment 
methods and participant flow through the study.
Patient and public involvement
Study questions and design were informed by patient 
contributors during four dedicated meetings. They high-
lighted the importance of clear information about the 
possible cause and prognosis of pain, as this is important 
to people with shoulder pain when planning their 
everyday life and considering treatment options. They 
stressed concern regarding the commonly used approach 
of ‘watchful waiting’. Postponing treatment/referral 
decisions was considered frustrating and unhelpful, 
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healthcare and personal costs. They expressed the need 
for a thorough assessment of shoulder pain, along with 
an early discussion of the possible benefits and draw-
backs of diagnostic procedures (eg, US) and treatment 
options. The group contributed to the design of the study 
by advising on recruitment processes, the content of data 
collection and how to explain the role of clinical assess-
ment and US to study participants. Annual Patient and 
Public Involvement and Engagement (PPIE) meetings 
are planned to ensure ongoing involvement and engage-
ment during data collection, analysis, interpretation and 
dissemination of findings.
Study population
Potential participants will be identified when they consult 
with an episode of shoulder pain at general practices, or 
NHS physiotherapy service (including self- referrers to 
physiotherapy) in five regions in the UK: Staffordshire, 
Cheshire, Oxfordshire, Birmingham and Gloucestershire. 
Recruitment of participants started in February 2019, 
with baseline data collection planned to be completed in 
September in 2021. Follow- up data collection is planned 
to be completed in September 2024.
Eligibility criteria
Potential participants must be registered at participating 
general practices or referred to NHS physiotherapy 
(including self- referrers), aged 18 years or over and 
presenting with a new episode of shoulder pain. Previous 
studies of shoulder pain in primary care indicate that 
many people consult quite late in the trajectory of their 
shoulder pain episode, with the median/mean duration 
of symptoms at presentation varying between 12 weeks 
and 1 year.4 5 21 22 Based on discussion with our clinical 
advisory group, a new care episode will be defined as no 
shoulder pain related consultation, no injection, surgery 
or physiotherapy- led exercise for shoulder pain, in the 
last 6 months, reflecting a point in time when primary 
care clinicians make (new) decisions regarding advice, 
treatment or referral.
Potential participants will be excluded on the basis of 
the following criteria:
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 ► Present to their GP or physiotherapist with symptoms 
or signs indicative of serious pathology (eg, fractures, 
infection).
 ► Have shoulder pain caused by stroke- related 
subluxation.
 ► Have a diagnosis of inflammatory arthritis (eg, rheu-
matoid arthritis or polymyalgia rheumatic).
 ► Have shoulder pain caused by cervical pathology.
 ► Are considered by the GP or physiotherapist to be 
vulnerable (eg, severe physical and/or mental health 
problems, dementia).
Recruitment
Potential participants consulting with shoulder pain will 
be identified through one of three methods:
i. Identification using an automated medical record 
template (pop- up) in GP sites, activated when a Read/
Systematised Nomenclature of Medicine (SNOMED) 
code for shoulder pain is entered into the medical 
record because of a patient consultation.
ii. Identification using an Egton Medical Information 
Systemts (EMIS) embedded ‘referral’ form which will 
autopopulate for eligible patients when triggered by 
the clinician in physiotherapy sites.
iii. Identification of patients from waiting lists for phys-
iotherapy. Referrals received from GPs, other health-
care professionals or self- referrals will be centrally 
triaged by senior physiotherapists using the PANDA- S 
eligibility checklist.
Potential participants will be asked for consent to 
share their contact details with the Keele Clinical Trials 
Unit who will send them a study pack, or a study pack 
will be sent directly from the GP or physiotherapy prac-
tices, depending on site preference. The study pack will 
contain: an invitation letter; a participant information 
leaflet; baseline questionnaire with consent form and 
eligibility screening questions; prepaid reply envelope.
Patients interested to take part in the study will be 
asked to complete the consent form and answer eligi-
bility questions relating to whether they have received 
treatment (eg, supervised exercise, injection, surgery) for 
their shoulder pain in the 6 months prior to consultation. 
Those who have not yet received treatment are eligible 
and invited to complete and return the baseline question-
naire. As this is an observational study, all participants will 
continue to receive care as usual for their shoulder pain.
Data collection
Data collection will be carried out by postal question-
naire at baseline, 3, 6, 12, 24 and 36 months. Since June 
2020, in response to the COVID-19 pandemic, follow- up 
questionnaires have also been made available as online 
surveys. Short- term data will be collected weekly through 
a specifically designed smartphone/tablet Shoulder Pain 
application (App) or text messages over 12 weeks. Clin-
ical data will be collected during a clinical assessment 
comprising a shoulder examination by a physiotherapist 
and an US. In response to the pandemic, face- to- face 
clinical assessments will be carried out (or paused) in 
accordance with national and local restrictions. Table 1 
provides an overview of the content and timing of data 
collection for this study.
Primary outcome measure
The primary outcome measure for investigating course, 
prognosis and treatment response is the SPADI.28 The 
SPADI is scored using a 0–10 Numerical Rating Scale 
(NRS) for each question from ‘no pain’ to ‘worst imag-
inable pain’ (for the pain scale) and from ‘no difficulty’ 
to ‘so difficult that help is required’ (for the disability 
scale). Numerical scores are summated and divided by 
the maximum score possible for all relevant questions 
and then multiplied by 100 to generate a score from 0 
to 100 with higher scores indicating worse shoulder pain 
and/or disability.
Secondary outcomes
Pain intensity will be measured on an NRS from 0 to 10 
asking the participant to report their worst pain in the 
past week. Sleep will be measured using the Jenkins Sleep 
Questionnaire.29 Global perceived change in shoulder 
pain since the baseline questionnaire will be asked in all 
follow- up questionnaires with one question providing 
participants with six possible response options from 
‘completely recovered’ to ‘much worse’. Work absence 
will be assessed through two methods:
 ► Employed participants will be asked if they are 
currently absent from work due to their shoulder 
pain, and, if so, for how long they have been absent.
 ► Fit note data for shoulder pain will be collected from 
the medical record (where participants have provided 
consent) allowing data on the number of days and 
number of episodes of clinician certified work absence 
to be collected.
Participants will also be asked to indicate how their 
shoulder pain has impacted on their work performance 
using the question ‘On average, to what extent has pain 
affected your performance at work in the past x months’30 
and are asked about attitudes and beliefs regarding 
health and work, measured using a new developed set of 
11 items.
Healthcare utilisation will be estimated based on self- 
report (follow- up) questionnaires, and include primary 
care consultations (GPs and practice nurses), secondary 
care consultations (eg, hospital consultants, physiother-
apists), prescriptions, hospital based procedures (diag-
nostic tests, injections and investigations) nature and 
length of inpatient stays, and surgery. Patients will be 
asked to distinguish between UK NHS and private provi-
sion. Finally, the EQ- 5D- 5L31 will be used to measure 
participants’ health- related quality of life.32
Candidate prognostic factors and moderators
Questionnaires will measure self- report candidate prog-
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Table 1 Data collection schedule (Self- Report Questionnaires)
Description
















  Severity of pain SPADI total score (5 
pain, 8 disability items, 
0–10 NRS, 0–100)
✓ ✓ ✓ ✓ ✓ ✓
  Severity of disability   ✓ ✓ ✓ ✓ ✓ ✓
Secondary outcome measures
  Sleep Jenkins sleep 
questionnaire (4 items, 3 
options each, 0–8)
✓ ✓ ✓ ✓ ✓ ✓
  Work absence How many days off work 
have you had in the past 
month (days/weeks)
✓ ✓ ✓ ✓ ✓ ✓
  Work performance Single item question 
(0–10)
✓ ✓ ✓ ✓ ✓ ✓
  Global perceived change Single item question (6 
options)
✗ ✓ ✓ ✓ ✓ ✓
  Health- related quality 
of life
EQ- 5D- 5L (5 items, 5 
options each)
✓ ✓ ✓ ✓ ✓ ✓
Sociodemographics
  Age Date of birth ✓ ✗ ✗ ✗ ✗ ✗
  Gender Male/female/prefer not 
to say
✓ ✗ ✗ ✗ ✗ ✗
  Education Highest qualification 
(single item, 5 options)
✓ ✗ ✗ ✗ ✗ ✗
  Health literacy Single item question (5 
options)
✓ ✗ ✗ ✗ ✗ ✗
  Work status 3 items ✓ ✗ ✗ ✓ ✓ ✓
Shoulder pain characteristics
  Side involved Left/right/both ✓ ✗ ✓ ✓ ✓ ✓
  History No of episodes in both 
shoulders (2 items, 4 
options)
✓ ✗ ✗ ✗ ✗ ✗
  Onset Acute versus gradual (2 
options)
✓ ✗ ✗ ✗ ✗ ✗
  Duration Single item question (6 
options)
✓ ✗ ✗ ✗ ✗ ✗
  Which is your dominant 
arm
Left/right ✓ ✗ ✗ ✓ ✓ ✓
  Continued shoulder pain 
at follow- up
Two single item 
questions
✗ ✗ ✗ ✓ ✓ ✓
  Pain elsewhere Full body manikin ✓ ✗ ✗ ✗ ✗ ✗
  Previous imaging for 
shoulder pain
Predefined list (4 options)             
  Previous shoulder pain 
treatments
Predefined list (6 options) ✓ ✗ ✗ ✗ ✗ ✗
  Analgesic use (over 
the counter and GP 
prescribed)
predefined list (10 
options)
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Description
















  Comorbidity Diabetes, insulin- 
dependent or not (3 
options)
✓ ✗ ✗ ✓ ✓ ✓
  Height and weight (BMI) Self- reported ✓ ✗ ✗ ✓ ✓ ✓
  Smoking and vaping 
(frequency)
Two single item 
questions (4 options 
each)
✓ ✗ ✗ ✓ ✓ ✓
  Alcohol consumption 
(frequency)
Single item question (6 
options)
✓ ✗ ✗ ✓ ✓ ✓
  Physical activity 
(frequency)
Single item question (7 
options)
✓ ✗ ✗ ✓ ✓ ✓
Work- related factors
  Most recent paid job title Single item question ✓ ✗ ✗ ✓ ✓ ✓
  Current work situation Single item question ✓ ✗ ✓ ✓ ✓ ✓
  Psychosocial work 
environment
Single component of 
the Work Organisation 
Assessment 
Questionnaire (4 items, 5 
options, 0–16)
✓ ✗ ✓ ✓ ✓ ✓
  Attitudes and beliefs 
towards work
Newly developed 
questionnaire, 11 items, 
7 options, 0–66)
✓ ✗ ✓ ✓ ✓ ✓
Psychosocial and behavioural factors
  Anxiety and depression Hospital Anxiety and 
Depression Scale (14 
items, 4 options each, 
0–42)
✓ ✓ ✓ ✓ ✓ ✓
  Fear of moving the arm Single item question 
(0–10 NRS)
✓ ✓ ✓ ✓ ✓ ✓
  Pain self- efficacy Pain Self Efficacy 
Questionnaire (10 items, 
7 options each, 0–60)
✓ ✓ ✓ ✓ ✓ ✓




questionnaire, 12 items, 
7 options, 4 subscales 
0–28)
✓ ✓ ✓ ✗ ✗ ✗
  Worry about shoulder 
pain
Single item question 
(0–10 NRS)
✓ ✓ ✓ ✓ ✓ ✓
  Treatment expectations 
(confidence)
List of potential 
treatment options (seven 
items, 0–10 NRS)
✓ ✗ ✓ ✓ ✓ ✓
Health economic measures
  Healthcare utilisation 




Self- reported (follow- 
up questionnaires; four 
items) and medical 
record review
✓ ✗ ✓ ✓ ✓ ✓
BMI, body mass index; EQ- 5D- 5L, European Quality of Life five Dimension ; GP, general practitioner; NRS, Numerical Rating Scale; SPADI, 
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(objectives 1, 3 and/or 5) which have been selected based 
on previous systematic reviews and cohort studies:
 ► Sociodemographic variables: age, gender, level of 
education, health literacy.33
 ► Shoulder pain characteristics: history, duration, onset 
and baseline severity of shoulder pain/disability; pain 
elsewhere (full body manikin).34
 ► Comorbidities and lifestyle: diabetes and other rele-
vant long- term conditions, height and weight to calcu-
late body mass index, smoking and vaping, alcohol 
consumption and physical activity.
 ► Work- related factors: current work status.
 ► Psychosocial and behavioural factors:
‒ Symptoms of anxiety and depression (Hospital 
Anxiety and Depression Scale).35
‒ Fear- avoidance beliefs, derived from the Fear- 
Avoidance and Beliefs Questionnaire,36 and worry 
about shoulder pain measured using single item 
questions.
‒ Pain self- efficacy (Pain Self Efficacy Questionnaire).37
‒ Cognitive and affective reassurance (Consultation- 
based Reassurance Questionnaire).38 39
‒ Treatment expectations: questions asking partici-
pants how confident they are that specified treatments 
will help their shoulder pain.
During the COVID-19 pandemic it is anticipated that 
participants’ responses to some questions may be influ-
enced by the pandemic or related restrictions, particu-
larly questions relating to current work status, ability to 
participate in usual activities, shoulder pain treatments, 
self- management of shoulder pain, anxiety and depres-
sion. To capture this, participants will be given the oppor-
tunity to comment on any conditions or circumstances 
that may have affected their responses in the follow- up 
questionnaires (open- ended question).
Medical record review
Participants will also be asked for consent to access and 
export aspects of their medical records, to provide infor-
mation on healthcare resource use including information 
on fit notes; prescriptions; consultation frequency; refer-
rals for further treatment and procedures (eg, imaging, 
surgery); non- shoulder- related musculoskeletal consul-
tations and other relevant comorbidity (coronary heart 
disease, diabetes, thyroid disease, cancer).
Follow-up data collection
Participants will be sent follow- up questionnaires at 3, 6, 
12, 24 and 36 months after the return of their baseline 
questionnaire; these follow- up questionnaires will be sent 
by post or a link to an online questionnaire will be sent 
by email. Non- responders to follow- up questionnaires will 
receive a reminder questionnaire after 2 weeks, 4 weeks 
and a telephone call a further 2 weeks later if no response 
has been received, with the option of completing a short 
(Minimum Data Collection) questionnaire by telephone, 
and if no telephone contact can be made, by post.
Short-term data collection
On return of the baseline questionnaire participants will 
be offered the option of completing the shoulder pain 
App or text messages reporting their pain and function 
(0–10 NRS) weekly for 12 weeks. The App also collects 
weekly data across eight further domains using single 
item questions: self- efficacy, work absence, mood, sleep, 
medication use, fear of movement, worry, treatment and 
recovery expectations.
Clinical assessment
Those participants who have returned a completed ques-
tionnaire will be offered the option to attend a clinical 
assessment by an experienced and trained physiothera-
pist, guided by a detailed manual and using a standardised 
case report form for data collection. Participants will be 
notified that all information collected at the clinic will be 
collected for research purposes, and that no recommen-
dations will be given regarding diagnosis, treatment or 
referral. Findings from the clinical assessment will only be 
discussed with their GP if the assessor feels there is a need 
for immediate clinical attention. In response to restric-
tions imposed during the coronavirus pandemic, ethical 
approval was requested (as an amendment to the original 
approval) to share a brief report from the US with the 
participants’ GPs. This may avoid the need for a separate 
referral for ultrasonography for clinical purposes in a 
context where there is a need to reduce physical contact 
and travel for non- essential purposes.
Physical examination
The assessment will include a standardised history based 
on questions regarding duration, severity, impact and 
(self) management of shoulder pain. The physical exam-
ination will include an examination of the neck using 
repeated movements through flexion, extension and 
side flexion to assess whether the patient’s shoulder pain 
is related to a neck problem. Shoulder range of move-
ment will be visually assessed (in degrees) during active 
abduction (in degrees) and external rotation, compared 
with the contralateral side. Additional tests designed to 
distinguish between different shoulder conditions have 
variable reliability and diagnostic test accuracy, but their 
selection was informed by systematic reviews:14 16 17
 ► Painful arc, Neer sign and Hawkins- Kennedy tests.
 ► External rotation lag sign.
 ► Glenohumeral external rotation (50% reduction 
compared with the less/non- painful side).
 ► Scapular assistance test.
 ► Empty Can and Full Can test.
 ► Scarf test and Bear Hug test
 ► Step- standing elevation.
 ► Muscle performance tests aiming to identify weakness 
and pain.
Anthropometric measurements will include height (in 
centimetres) and weight (in kilograms) and waist- hip 
circumference (in cm). To assess balance, strength, and 
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consisting of grip strength, lower limb strength (sit- to- 
stand) and a balance test.
Following the assessment, the research physiotherapist 
will record their opinion regarding the pathoanatom-
ical classification of the shoulder problem (rotator cuff 
disorder, frozen shoulder, glenohumeral osteoarthritis, 
acromioclavicular joint pain, instability, neck- related 
dysfunction), and rate their confidence in this classifi-
cation using a 0–10 NRS. The physiotherapist will also 
estimate the participant’s prognosis, through answering 
the question ‘Do you think this participant will have inter-
fering shoulder pain in 6 months’ time? Yes/No/Don’t 
know’.
Ultrasound assessment
The US will be performed by experienced ultrasonog-
raphers/radiologists using high- resolution ultrasound 
systems and transducers40 according to a standardised 
scanning protocol.41 The structures scanned will include 
long head of biceps tendon, rotator cuff (subscapularis, 
supraspinatus, infraspinatus and teres minor tendons 
and muscles), posterior glenohumeral joint, subacro-
mial/deltoid bursa and acromioclavicular joint. A 
standardised structured report based on42 will include 
information regarding tendon and bursal pathology 
including structural appearances, site and size of tendon 
tears, observed glenohumeral or acromioclavicular fluid, 
synovitis or cortical bone changes and muscle atrophy. 
Dynamic scanning of some shoulder movements will be 
performed to assess for restriction or instability. Colour 
Doppler will be used to assess the presence of neovas-
cularisation in any areas of tendon, sheath or bursal 
abnormality. Both shoulders will be scanned to enable 
later analysis of abnormalities in affected versus pain- free 
shoulders.
Qualitative interview study
Recruitment of patient-clinician dyads
Patient- participants: Questionnaires will be screened 
to enable a purposive sampling frame to be applied. A 
range of participant characteristics will be sampled for, 
including age, sex, reported pain intensity, pain duration, 
shoulder diagnoses, socioeconomic status, health literacy 
and Fit Note status (ie, absent from work or not). Partic-
ipants who are selected for interview will be sent an invi-
tation letter, reply slip and participant information leaflet 
about the interview. Those who return a reply slip indi-
cating a willingness to be interviewed will be telephoned 
to arrange the interview.
Clinician participants: As part of the patient- participant 
consent process, the participant will be asked the name 
of the clinician with whom they consulted for their 
shoulder pain (GP or physiotherapist) and for permission 
to contact the clinician to arrange a separate individual 
interview in which the consultation will be discussed. If 
a participant declines consent to contact their clinician, 
then the participant’s interview will be used alone.
Data collection
Topic guides will be used in interviews, which will be 
informed by the study objectives and the future aim 
of designing an optimal (stratified) model of care for 
shoulder pain, and by previous research on participant- 
clinician communication, effective reassurance and diag-
nostic and prognostic uncertainty in musculoskeletal 
pain.38 43 44 Separate topic guides are developed for partic-
ipant and clinician interviews. Clinicians will be asked 
about their views and experiences of treating shoulder 
pain, particularly in relation to the given consultation 
(online supplemental file 1). Topic guides will be itera-
tively revised throughout the data- collection process in 
light of emergent findings.
Topics will include (but not be limited to):
 ► Participants’ experiences of managing their shoulder 
pain condition and its impact on their lives.
 ► Participants’ understanding of possible causes of 
shoulder pain, including the ‘label’ attached to expla-
nations and identified issues associated with this.
 ► The value participants and clinicians attribute to 
diagnostic tests, including physical examination and 
imaging.
 ► Consideration of explanations, concerns and uncer-
tainty regarding prognosis.
 ► Views on decisions and advice given about self- 
management, work and other activities.
 ► Clinician–patient communication regarding diag-
nosis, prognosis and treatment options.
 ► Participants’ and clinicians’ views and experiences 
regarding the impact of the coronavirus pandemic on 
management of shoulder pain and on treatment and 
referral decisions.
Semistructured interviews will be carried out with 
approximately 15 participant–clinician dyads (ie, approx-
imately 30 interviews in total). The final number of inter-
views will be guided by data saturation, defined in terms 
of ‘informational redundancy’45—the point at which 
additional data no longer offers new insights.
Analysis cohort study (objectives 1–5)
A detailed analysis plan will be written for each of the 
study objectives; a summary is given here. Most analyses 
will be conducted using Stata software v16.
Objective 1
Investigate pain and function trajectories (overall prog-
nosis): Descriptive statistics (estimates and measures of 
dispersion) will be used to report baseline characteristics 
of the study population, and the course of symptoms over 
time, for the primary outcome (SPADI) and secondary 
outcome measures. For each follow- up time point (0, 
3, 6, 12, 24, 36 months), we will report means (SD) for 
continuous outcomes, and proportions (n, %) for binary 
outcomes, based on longitudinal models that account 
for correlated responses over time. Attrition (n,%) 
will be described for each follow- up time point. Base-
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(whose outcomes are hence not fully observed) will be 
summarised and compared with characteristics of those 
remaining in the study to assess for risk of attrition bias.
Latent class growth analysis or other latent trajectory 
analysis will be used to identify distinct groups of partici-
pants with similar short- term trajectories of shoulder pain 
and function scores (0–10 NRS) using weekly measure-
ments of outcome data at up to 12 time points over the 
first 3 months. For inclusion in the analysis, participants 
will be required to have available data in week 1 and at ≥2 
further time points. The optimal number of trajectories 
will be selected using a combination of statistical, parsi-
mony and interpretability criteria.46
Appropriate polynomial functional form for each 
trajectory will be chosen, based on the significance of 
the estimated parameters related to each polynomial 
component. Participants will be assigned to trajectories 
according to maximum probability assignment principle. 
The number of trajectories will be increased, and model 
fit assessed using Bayesian information criterion (BIC) 
and sample size adjusted BIC. The Lo, Mendell and Rubin 
adjusted likelihood ratio test (LRT),47 and the bootstrap 
LRT were used to assess whether there was a significant 
improvement in model fit between k-1 and k trajec-
tory models. The following criteria will also be used for 
model selection: (1) delineation of trajectories assessed 
by higher entropy, (2) average posterior probability of 
trajectory membership >0.7, (3) trajectory member-
ship ≥4% and (4) clinical relevance and interpretation of 
the identified trajectories. Mplus software is planned to 
be used for analysis of pain and function trajectories.48
Baseline characteristics of subgroups showing distinct 
trajectories will be described, including any treatment 
received for shoulder pain during the first 3 months. 
Similar methods will be used to describe long- term trajec-
tories, using outcome data at 6, 12, 24 and 36 months. 
Based on previous studies investigating trajectories in 
other conditions (n=350–700)49 50 we expect to identify 
between three and five classes, for which a sample size 
between 400 and 500 participants should be sufficient. 
The GRoLTS checklist for reporting latent trajectory 
studies will be followed.51
Objective 2
Describe healthcare resource use and productivity 
losses: Healthcare costs will be estimated by combining 
resource use data with unit costs, obtained from stan-
dard sources including the British National Formulary 
for drugs,52 NHS Reference costs53 and Unit Costs of 
Health and Social Care.54 Productivity costs will be esti-
mated using the human capital approach with salary costs 
based on respondent job- specific average wage estimates 
identified from annual earnings data and UK Standard 
Occupational Classification coding.55 Responses to the 
EQ- 5D- 5L at each time point will be converted to utility 
values obtained using the cross- walk value set, in line with 
current National Institute for Health and Care Excellence 
recommendations.56 Utility values will also be converted 
into quality- adjusted life- years (QALYs) using the area 
under the curve approach linking utility scores at various 
time points. A descriptive analysis of resource use, health-
care costs, time off work, productivity costs, EQ- 5D- 5L 
utility values and total QALYs will be conducted, with 
presentation of means and confidence intervals obtained 
by non- parametric bootstrapping.
Objective 3
Develop a prognostic model for predicting individuals’ 
level and risk of pain and disability: We will develop and 
validate a multivariable prediction model for reliably esti-
mating expected levels of pain and disability (using SPADI 
total score as a continuous outcome) over 6 months 
follow- up. Development of prognostic prediction model 
will be guided by the PROGRESS framework57–59 and 
reported using Transparent Reporting of a multivariable 
prediction model for Individual Prognosis or Diagnosis 
reporting guidelines. The number of variables (candi-
date predictors) for potential inclusion will be restricted 
to meet sample size requirements (see below), based on 
existing or emerging evidence regarding the prognostic 
value of variables, combined with clinical and patient 
expertise, and consider sociodemographic variables, life-
style factors, shoulder pain characteristics, comorbidity 
and psychosocial factors. Candidate predictors will be 
based on participant self- report to allow wide App of the 
prognostic model, with data extracted from the baseline 
questionnaire. Multivariable linear regression using the 
elastic net penalty (to penalise for potential overfitting 
and to allow variable selection). Continuous prognostic 
variables will not be categorised during the process of 
developing the models, with splines or fractional poly-
nomials used to examine non- linear associations with 
outcome. Prognostic subgroups will be defined based on 
predicted SPADI values at 6 months, using a priori defined 
thresholds for SPADI for recovery (eg, SPADI score <20) 
or persistent high levels of pain and disability (eg, SPADI 
score ≥50). We will additionally describe predictive 
performance of the model to accurately predict the prob-
ability of individuals with shoulder pain to experience 
recovery and risk persistent high SPADI scores. Internal 
validation will be undertaken using bootstrapping of the 
entire development dataset, and optimism- adjusted esti-
mates of predictive performance produced for calibra-
tion (eg, R2, calibration- in- the- large, calibration slope) 
and discrimination (eg, C- statistic, area under the curve) 
for predicted risks.
We have estimated minimum sample size using the 
approach proposed by Riley et al,60 61 and using the Stata 
pmsampsize command, aiming to reduce overfitting 
of the prediction model. Based on previous studies, we 
expect R2 to be 0.5 when including baseline level of the 
primary outcome (SPADI total score) in the model as 
planned. Based on an expected mean change of 25 points 
and SD of 235 and a model including 20 candidate predic-
tors, the required minimum sample size is 254 partici-
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recruit at least 339 participants to the cohort. When using 
a binary outcome, a minimum sample size of 377 partici-
pants with follow- up (503 at baseline) would be needed.
Objective 4
Explore the added prognostic value of physical examina-
tion tests and US findings: Due to lockdown measures 
during the COVID-19 pandemic, a much smaller number 
of participants than originally planned can be invited for 
a clinical assessment. Given the expected small sample 
size, the statistical analysis of data from the clinical assess-
ment will focus on testing a priori defined hypotheses, 
informed by previous literature and clinical expertise, 
and explore the value of adding specific physical exam-
ination tests or US findings for predicting outcome 
(higher SPADI scores over 6 months follow- up), over and 
above prognostic information included in the predic-
tion model using self- report data only. Assuming R2 from 
the prediction model will be 0.5 using 20 predictors (as 
described above), to have 80% power to detect one addi-
tional predictor adding 0.05 to the R2 to the model, we 
would need 74 participants without drop- out, and 99 
participants assuming 25% will drop- out.62
Objective 5
Explore candidate predictors of response to commonly 
used treatments in a real- life, observational setting: 
Developmental work (systematic review, workshops with 
clinicians and international choice- based conjoint- survey 
of clinicians)63 has generated a shortlist of candidate 
treatment moderators that may modify the response to 
commonly used treatments for shoulder pain in primary 
care (advice and pain relief only, corticosteroid injection, 
exercise/mobilisation), as recorded by participants in 
the three and 6 months follow- up questionnaires. These 
candidate moderators will include: symptom duration; 
presumed cause of shoulder pain (injury or other); 
coexisting neck pain; psychosocial complexity (fear- 
avoidance, catastrophising, anxiety, depression); positive 
expectations or preferences regarding treatment and 
comorbidity (in particular diabetes). Linear (random 
effects) regression analysis will be used to estimate the 
outcomes of treatment received (eg, corticosteroid injec-
tion compared with advice/analgesics only), using SPADI 
score over 6 months follow- up as the primary outcome. 
Propensity score methodology (using matching, strat-
ification or inverse probability of treatment weighting 
approach) will be used to adjust for confounding by 
indication due to observed covariates. Sensitivity analysis 
will be performed to assess the robustness of findings to 
potential unmeasured confounding, using the E value 
approach.64 The effects of moderator*treatment interac-
tions will be explored, and overall treatment outcomes 
as well as outcomes for relevant subgroups (where rele-
vant moderator*treatment interactions will be identified) 
described. Based on previous primary care studies7 and 
our GP survey65 we expect that 20%–40% of patients 
receive an injection and 25%–50% of patients see a 
physiotherapist following GP consultation. Depending 
on the distribution of candidate predictors, this will give 
subgroups of ≥100 to explore the role of candidate moder-
ators. These are exploratory analyses, given that predic-
tors of treatment effect need to be confirmed using data 
from randomised trials, but will offer insight into their 
value in the broader population of people with shoulder 
pain presented in routine primary care.
Missing data
For all quantitative analyses patterns of missing data will be 
described. Under a ‘missing- at- random’ assumption, indi-
viduals with partially missing outcome data (eg, at some 
time points) will be included in analyses (without imputa-
tion) using a longitudinal data (hierarchical) modelling 
framework. If there is a considerable amount of missing 
baseline data for candidate predictors or covariates of 
interest this will be handled using multiple imputation, 
and Rubin’s rules used to combine results across imputed 
datasets. The imputation will be conditional on observed 
outcomes and candidate predictors, and auxiliary vari-
ables, to help ensure a ‘missing- at- random’ assumption 
is appropriate.
Analysis qualitative study (objective 6)
All interviews will be audiorecorded, fully transcribed and 
then cleaned and anonymised. An inductive, exploratory 
framework will be adopted using thematic analysis and 
influenced by grounded theory.66 The constant compar-
ison method67 will be used in the analysis, looking for 
connections within and across interviews, and across 
codes, highlighting data consistencies and variation.
The participant–clinician dyad will be the unit of anal-
ysis. Exploring dual perspectives on the consultation can 
provide a rich data source which can strengthen trustwor-
thiness of data.68 Comparisons will be made between the 
matched participant and clinician interviews, looking for 
similarities and differences in the separate accounts given. 
Analysis will, therefore, draw comparisons both between 
clinician and participant perceptions of specific consul-
tations as well as between different clinician–participant 
dyads across the sample.
DISCUSSION
This study protocol describes a prospective cohort study 
investigating the course and prognosis of shoulder pain 
in primary care, as well as healthcare costs and produc-
tivity losses associated with an episode of shoulder pain. 
The study includes a linked qualitative study, interviewing 
dyads of patients and their clinicians about the influences 
on decision making and their perspectives on the impor-
tance of diagnostic and prognostic information in the 
management of the shoulder problem. Recruitment is 
expected to be completed in July 2021.
The cohort study is part of a programme of work 
aiming to improve patient outcomes and healthcare 
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to treatments from which they are likely to benefit most. 
The cohort study will provide insight into the content and 
outcomes of current primary care for patients presenting 
with shoulder pain, describe overall prognosis and use 
self- report information from participants to develop 
a prognostic model for predicting future levels of pain 
and disability in individuals with shoulder pain, allowing 
early identification of those who can be reassured and 
self- manage their shoulder condition, as well as those 
who are at risk of persistent pain and disability and would 
benefit from further treatment. The PANDA- S research 
programme also includes an individual participant data 
(IPD) meta- analysis of randomised trials to test candidate 
predictors of the effect of commonly used treatments for 
shoulder pain.69 The data from the cohort study, linked 
qualitative study, and IPD meta- analysis will then be used 
to co- design, together with clinicians and patients, a prog-
nostic screening and treatment decision tool to inform 
improved decision making for people presenting with 
shoulder pain. The use of the tool will subsequently be 
evaluated in a multicentre, pragmatic randomised trial.
The coronavirus pandemic, including restrictions 
required to reduce the risk of infection, has impacted 
significantly on recruitment and data collection for the 
cohort study. Recruitment to the PANDA- S cohort study 
had to be paused between March and August 2020. 
Recruitment gradually restarted in GP practices after this 
lockdown period but was significantly impacted by further 
restrictions implemented in November 2020 and again in 
January 2021, resulting in fewer patients accessing health 
services for shoulder pain. Recruitment was additionally 
affected by increasing pressures on GP services, including 
illness of staff and patients, dealing with the conse-
quences of limited access to care, and contribution to 
the vaccination programme. Recruitment through phys-
iotherapy waiting lists was therefore initiated in February 
2021. All changes to protocol and recruitment targets 
were discussed with our Programme Steering Committee. 
Postal questionnaires were converted to online surveys, 
and reminder processes were amended from paper 
versions to telephone and online reminders. Addition-
ally, questionnaires were amended to include a comments 
section allowing participants to record any circumstances 
that may have affected their responses, as we expected 
that COVID-19- related restrictions would impact on their 
access to care, ability to work and exercise, and on their 
mental health and well- being.
Face- to- face research clinics could only be resumed in 
April 2021, limiting the number of patients that can be 
offered a physical examination and US within the time 
frame of the study. We initially planned to incorporate 
data from the clinical assessment (physical examination 
test results and US findings) in the development of the 
prediction model, requiring a minimum sample size of 
more than 250 attending research clinics (see analysis 
plan for objective 3). Given the expected smaller number 
of participants attending clinic, the statistical anal-
ysis of physical examination tests and US findings will, 
therefore, focus on testing specific hypotheses regarding 
the prognostic value of a limited number of these diag-
nostic tests over and above a prediction model based on 
self- report findings. The results will inform the develop-
ment of recommendations regarding relevant tests to 
perform during a clinical assessment, and regarding the 
value of US findings in making decisions regarding treat-
ment and referral. The prognostic model will be based on 
self- report information only, which will allow the future 
screening tool to be used during remote as well as face- to- 
face consultations with healthcare professionals.
Ethics and dissemination
The PANDA- S study has ethical approval from Yorkshire 
and The Humber- Sheffield Research Ethics Committee 
(18/YH/0346, IRAS Number: 242750). Results will be 
disseminated through peer- reviewed publications, social 
and mainstream media, professional conferences and the 
patient and public involvement and engagement group 
supporting this study and through newsletters, leaflets 
and posters in participating sites.
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